Galderma 보도자료 - 뉴스와이어

Galderma 보도자료

RSS

131개

2024년 7월 25일 17:25

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024. · Record net sales ...

제약 실적

2024년 7월 25일 15:31

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis - Itch, Skin Lesions and Sleep Disturbance

Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet .[ ...

임상시험 제약 조사분석

2024년 6월 19일 16:55

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the ...

제약 인증

2024년 5월 23일 14:36

Galderma Launches Restylane® VOLYME™ in China - One of the World’s Fastest Growing Aesthetics Markets

Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introduc ...

제약 미용 신상품

2024년 5월 7일 14:35

Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adol ...

제약 인증

2024년 4월 24일 14:34

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. · Re ...

제약 실적

2024년 3월 19일 15:19

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aest ...

임상시험 제약 연구개발

2024년 3월 11일 09:15

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodu ...

임상시험 제약 연구개발

2024년 2월 29일 15:36

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Galderma: Delivered against full year guidance for another consecutive year with strong financial performance · Galderma achieved net sales of 4.0 ...

제약 실적

2024년 2월 28일 17:02

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Der ...

임상시험 제약 연구개발

2024년 2월 14일 16:24

CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Correction by Galderma: Results from the OLYMPIA program demonstrated that more than half of nemolizumab-treated patients achieved an at least fou ...

제약 인증

2024년 2월 8일 15:32

Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week

Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersio ...

제약 신상품

2024년 2월 7일 15:12

Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics

Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep- ...

의료와 병원 제약 조사분석

2024년 2월 4일 10:51

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS

Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare pr ...

제약 미용 회사 공지

2024년 2월 2일 16:02

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS

Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare pr ...

제약 회사 공지

2024년 1월 26일 09:30

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science ( ...

의학 제약 연구개발

2024년 1월 22일 15:35

Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region

Galderma, the emerging pure-play dermatology category leader, announced today it has received approval from Health Canada for Restylane® SHAYPE™, ...

제약 인증

2024년 1월 17일 15:57

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the t ...

임상시험 제약 연구개발

2023년 11월 30일 15:36

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL - f ...

제약 의료와 병원 연구개발

2023년 11월 21일 16:35

Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories

Galderma: ·Galderma achieved net sales of 3,009 M USD over the first nine months of 2023, up 8.9% year-on-year on a constant currency basis ·Conti ...

제약 실적

2023년 10월 26일 14:25

Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the eff ...

제약 조사분석

2023년 10월 15일 11:11

Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event

Galderma, the emerging pure-play dermatology category leader, today hosts the first edition of its Liquid Live event in Dubai as a chance to discu ...

제약 행사

2023년 10월 12일 11:24

Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis - ARCADIA 1 and 2 and OLYMPIA 1, r ...

제약 의료와 병원 조사분석

2023년 10월 4일 15:05

EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology

Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative d ...

제약 의료와 병원 조사분석

2023년 10월 3일 11:57

Galderma announces progress with RelabotulinumtoxinA regulatory submissions

Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics ...

제약 사업 확장

메뉴 닫기